Real-Time US-CT fusion imaging for guidance of thermal ablation in of renal tumors invisible or poorly visible with US: results in 97 cases

Mauri, Giovanni; Monfardini, Lorenzo; Vigna, Paolo Della; Montano, Florian; Bonomo, Guido; Buccimazza, Giorgio; Camisassi, Nicola; Rossi, D; Maiettini, Daniele; Varano, Gianluca Maria; Solbiati, Luigi; Orsi, Franco

doi:10.1080/02656736.2021.1923837

Cited by 12 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, CT imaging has better tissue penetration, is more cost-effective, and can perform three-dimensional vascular reconstruction. Thus, US/CT dual-modal imaging is highly promising for improving real-time imaging contrast, acquiring clinical application anatomical information, and guiding and monitoring tumor ablation [ 122 – 124 ]. Yuan et al [ 125 ] developed a multifunctional nanodrug delivery system with multiple therapeutic and imaging functions.…”

Section: Cancer Theranosticsmentioning

confidence: 99%

Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics

et al. 2021

View full text Add to dashboard Cite

Polydopamine (PDA), which is derived from marine mussels, has excellent potential in early diagnosis of diseases and targeted drug delivery owing to its good biocompatibility, biodegradability, and photothermal conversion. However, when used as a solid nanoparticle, the application of traditional PDA is restricted because of the low drug-loading and encapsulation efficiencies of hydrophobic drugs. Nevertheless, the emergence of mesoporous materials broaden our horizon. Mesoporous polydopamine (MPDA) has the characteristics of a porous structure, simple preparation process, low cost, high specific surface area, high light-to-heat conversion efficiency, and excellent biocompatibility, and therefore has gained considerable interest. This review provides an overview of the preparation methods and the latest applications of MPDA-based nanodrug delivery systems (chemotherapy combined with radiotherapy, photothermal therapy combined with chemotherapy, photothermal therapy combined with immunotherapy, photothermal therapy combined with photodynamic/chemodynamic therapy, and cancer theranostics). This review is expected to shed light on the multi-strategy antitumor therapy applications of MPDA-based nanodrug delivery systems. Graphical Abstract

show abstract

Section: Cancer Theranosticsmentioning

confidence: 99%

Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Image-guided ablations, such as MWA, RFA, MWA plus RFA, CA and laser ablation have significantly progressed over the past years and they represent a useful toolbox for a multimodal approach to this disease [15,[20][21][22][23][24]. The most common shared indications…”

Section: Discussionmentioning

confidence: 99%

Image-Guided Ablations in Patients with Recurrent Renal Cell Carcinoma

Aurilio

Mauri

Rossi

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is one of the most frequently diagnosed tumors and a leading cause of death. The high risk of local recurrence and distant metastases represent a significant clinical issue. Different image-guided ablation techniques can be applied for their treatment as an alternative to surgery, radiotherapy or systemic treatments. A retrospective analysis was conducted at our institution, including a total number of 34 RCC patients and 44 recurrent RCC tumors in different locations (kidney, lung, adrenal gland, liver, pancreas, pararenal and other) using microwave ablation, radiofrequency ablation, cryoablation and laser ablation. The estimated time to local and distant tumor progression after treatment were 22.53 ± 5.61 months and 24.23 ± 4.47 months, respectively. Systemic treatment was initiated in 10/34 (29%) treated patients with a mean time-to-systemic-therapy of 40.92 ± 23.98 months. Primary technical success was achieved in all cases and patients while the primary efficacy rate was achieved in 43/44 (98%) cases and 33/34 (97%) patients, respectively, with a secondary technical success and efficacy rate of 100%. At a mean follow-up of 57.52 months ± 27.86 months, local tumor progression occurred in 3/44 (7%) cases and distant progression in 25/34 (74%) patients. No significant complications occurred. Image-guided ablations can play a role in helping to better control recurrent disease, avoiding or delaying the administration of systemic therapies and their significant adverse effects.

show abstract

“…For these reasons, US-CT fusion imaging can be used for guidance during ablation of RCC [ 16 ]. For example, Mauri et al [ 17 18 ] reported that US-CT image fusion guidance allows for correct tumor targeting of renal tumors that are poorly visible, inconspicuous, or invisible with US alone. However, in that study, the RFA procedure did not use only US-CT fusion imaging guidance, and CT scans were simultaneously performed to confirm the position of the inserted electrode needle.…”

Section: Discussionmentioning

confidence: 99%

Radiofrequency ablation using real-time ultrasonography–computed tomography fusion imaging improves treatment outcomes for T1a renal cell carcinoma: Comparison with laparoscopic partial nephrectomy

2022

View full text Add to dashboard Cite

Purpose To determine whether real-time ultrasonography–computed tomography (US-CT) fusion imaging can improve technical feasibility versus B-mode US and provide comparable outcomes of radiofrequency ablation (RFA) for T1a renal cell carcinoma (RCC) compared with laparoscopic partial nephrectomy (LPN). Materials and Methods Between June 2013 and August 2016, biopsy- or pathologically confirmed stage T1a RCCs were retrospectively reviewed. Of these, 39 cases were included in the RFA group, and 46 cases were included in the LPN group. In the RFA group, we evaluated tumor visibility and technical feasibility before RFA on a four-point scale on B-mode US and US-CT fusion images. After RFA, hospital days, creatinine value, complications, and disease-free survival rate were compared between the two groups. All results were analyzed by use of the Mann–Whitney U-test and Kaplan–Meier method. Results Compared with B-mode US alone, real-time US-CT fusion significantly improved the tumor visibility score and overall mean technical feasibility grade (p<0.001). The 5-year disease-free survival rate was 97.4% and 97.8% in the RFA and LPN groups, respectively, and there was no statistically significant difference between groups (p=0.1). Mean periprocedural creatinine levels were significantly lower in the RFA group than in the LPN group. The number of hospital days was shorter in the RFA group. Minor complications were present in 5.1% of the RFA group and 13.0% of the LPN group, with no major complications. Conclusions US-CT fusion-image-guided RFA improved tumor visibility scores and overall mean technical validity and resulted in a comparable disease-free survival rate to LPN.

show abstract

Real-Time US-CT fusion imaging for guidance of thermal ablation in of renal tumors invisible or poorly visible with US: results in 97 cases

Abstract: Orsi (2021) Real-Time US-CT fusion imaging for guidance of thermal ablation in of renal tumors invisible or poorly visible with US: results in 97 cases,

Cited by 12 publications

References 29 publications

Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics

Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics

Image-Guided Ablations in Patients with Recurrent Renal Cell Carcinoma

Radiofrequency ablation using real-time ultrasonography–computed tomography fusion imaging improves treatment outcomes for T1a renal cell carcinoma: Comparison with laparoscopic partial nephrectomy

Contact Info

Product

Resources

About